Corporate Philosophy System

At Torii, while carrying forward the corporate culture and the trust of each stakeholder we have built up throughout our long history, we have defined our Corporate Philosophy as Torii Pharmaceutical's Purpose to express our unchanging ambitions for the future. We place TORII's POLICY as our important values and the 4S MODEL as our fundamental management stance, and strive to fulfill Torii Pharmaceutical's Purpose.

Corporate Philosophy Torii Pharmaceutical's Purpose

We are committed to sincerely serving patients, their families, and those involved in medical care. We contribute to the healthy recovery of patients, as well as to a happy, enriched life free from fear of illness.

We will flexibly change and adapt to meet the needs of the times and the environment, while retaining the trust we have earned over our long history, and we will continue to take on the challenge of contributing to healthcare that only we can make.

Our Important Values TORII's POLICY

- Treasure all human connections
- Sincerity and commitment are Torii's finest qualities
- We all have a stake. We all have a role
- Try new things without fear
- All of our past experiences fuel our continued growth

Basic Management Stance

4S MODEL

Through the circulation/expansion of capital generated by our high-quality business activities, we will fulfill our responsibilities to our customers, shareholders, society, and employees in a balanced way and enhance their overall satisfaction.



(Note) 4S is the collective term for CS, IS, SS, and ES.

CS (Customer Satisfaction): Our Responsibility to Customers We strive to improve the quality of life (QOL) of patients

by supplying superior medicines and accurate information through medical professionals.

IS (Investor Satisfaction): Our Responsibility to Shareholders

We disclose timely, accurate corporate information and endeavor to generate appropriate shareholder returns and improve our corporate value.

SS (Social Satisfaction): Our Responsibility to Society

We maintain a high ethical standard regarding our corporate social responsibility through business activities that reflect the needs of society.

ES (Employee Satisfaction): Our Responsibility to Employees

We aim to provide motivation and fulfillment to all our employees by respecting every individual, ensuring equal opportunities for career advancement, and by treating employees fairly on the basis of unbiased assessments.

CONTENTS

Introduction

- 1 Corporate Philosophy System
- 2 Contents
- 3 The History of Torii
- 4 Torii in Numbers

Sustainability 19 Sustainability

- 20 Materiality
- 21 CS Our Responsibility to
- Customers 24 IS Our Responsibility to
- Shareholders 26 (SS) Our Responsibility to
- 28 ES Our Responsibility to Employees

Corporate Governance

30 Directors

- 31 Skill Matrix / Organization
- 32 Message from the Executive Deputy President
- 34 Corporate Governance
- 38 Message from Outside Directors
- 41 Compliance
- 42 Risk Management

Data Section

- 44 Financial Data
- 51 ESG Data
- 52 Corporate Information
- 53 Stock Information

Editorial Policy

This Integrated Report has been published to provide a comprehensive range of financial and non-financial information to further enhance understanding of Torii's activities among shareholders, investors, and various other stakeholders.

More detailed information on Torii is disclosed on our corporate website. https://www.torii.co.jp/en/

Period covered by this report:

Value Creation Stories

6 Message from the President

13 Medium-/Long-Term Business Vision

16 Medium-Term Management Plan

Risks and Opportunities

18 Recognition of the External Environment /

10 Value Creation Process

11 Capital Strategy

12 Business Model

"VISION2030" 14 Business Strategy

> Fiscal 2023 (from January 1, 2023 to December 31, 2023) Some information on and after January 2024 is included. Organizational scope: Torii Pharmaceutical Co., Ltd. Date of publication: June 2024 Reporting guidelines, etc.:

The International Integrated Reporting Framework; IFRS Foundation Guidance for Integrated Corporate Disclosure and Company-Investor Dialogue For Collaborative Value Creation; Ministry of Economy, Trade and Industry

Cautionary statement

The forecasts presented in this report are forward-looking statements. Reflecting assumptions based on information available on the date of disclosure, these statements are subject to inherent risks and uncertainties. Accordingly, unforeseen factors may cause actual results to differ materially from the projections contained herein. Torii will not necessarily revise this material regardless of any new information, future events or other results. Introduction

The History of Torii

Since its founding in 1872, Torii has undergone reforms through flexible ideas and smart action without being limited to the past, while also valuing the trust it has cultivated through more than 150 years of business.

Going forward, we will continue to take on challenges to make contributions to the medical field that are unique to Torii.

2009 2014 Oral anti-pruritus agent Launch of REMITCH Capsules

Agent for hyperphosphatemia Launch of Riona Tablets

_ 2015

House dust mite allergy (allergen



2020 Therapeutic agent for Anemia Associated with CKD Launch of ENAROY Tablets



Skin disease

1975 Topical corticosteroid Launch of LOCOID Ointment and Cream

-1993 Topical corticosteroid Launch of ANTEBATE ointment and cream



2020 Topical Janus kinase (JAK) inhibitor Launch of CORECTIM ointment



Allergens

1963 Allergy diagnosis and immunotherapy drug Launch of ALLERGEN (allergenic extracts)

1949

Torii Events

1872 Tokubei Torii established a company named Uenoya, at Sakai-Machi, Yokohama, for import of pharmaceuticals from the West.

1909

Establishment of Uenoya's research laboratories, and start of dealing in Japanese pharmacopoeial drugs under the Torii brand name



1911 Establishment of branch office (the current head office) in Nihonbashihoncho, Chuo-ku, Tokyo.

Company name changed to Torii Pharmaceutical Co., Ltd. 1963 Torii went public with over-the-counter stock transactions at the Tokyo Securities Dealers Association. 1977 A new plant constructed at Sakura,

Chiba Prefecture.

1983 Merck & Co., Inc. purchased more than 50% of Torii's stock and became a parent company.

1988 Asahi Breweries, Ltd. purchased more than 50% of Torii's stock and became a

parent company. 1990

Current Head Office building completed.

1993

Torii's stock listed on the second section of the Tokyo Stock Exchange.

2014

immunotherapy)

Japanese cedar pollinosis (allergen

Launch of CEDARTOLEN SUBLINGUAL

DROP — Japanese Cedar Pollen *Discontinued in 2021

1995 Torii's stock listed on the first section of the Tokyo Stock Exchange.

1998

Japan Tobacco Inc.(JT) purchased more than 50% of Torii's stock and became a parent company.

1999 JT and Torii established a collaboration arrangement (Torii concentrates on marketing and JT, on R&D.)

2019 A license agreement for Torii's exclusive sales rights in Japan for six anti-HIV drugs comes to an end

2020 Torii transferred Sakura Plant to IWAKI SEIYAKU CO., LTD.

2022

Torii's stock transferred from the First Section of the Tokyo Stock Exchange to the Prime Market due to the revision of market segments



Other

2018

Japanese cedar pollinosis

2021

Launched ORLADEYO Capsules, a plasma kallikrein inhibitor indicated for the suppression of the attacks in hereditary angioedema (HAE)



1921 Uenoya reorganized as Torii Shoten K.K.

Torii in Numbers

Mainstay Products

Allergens

Japanese cedar pollinosis (Allergen immunotherapy)




CEDARCURE is an allergen immunotherapy drug for Japanese cedar pollinosis. This fast-dissolving sublingual tablet is available for adult and pediatric patients.

MITICURE

House dust mite allergy (Allergen Immunotherapy)



MITICURE is an allergen immunotherapy drug for house dust mite-induced allergic rhinitis. This fast-dissolving sublingual tablet is available for adult and pediatric patients.



Net Sales by Disease Area

(99.5%)

Renal disease and hemodialysis

Riona Tablets

Agent for hyperphosphatemia/Iron-deficiency anemia



Riona is a medication with two indications: hyperphosphatemia in patients with chronic kidney disease, including hemodialysis, peritoneal dialysis, and non-dialysis chronic kidney disease patients, and iron deficiency anemia.

REMITCH Oral anti-pruritus agent



REMITCH is a treatment for pruritus in patients on dialysis and with chronic liver disease for which conventional antipruritic medications are ineffective.

Skin disease

CORECTIM Topical Janus kinase (JAK) inhibitor



CORECTIM Ointment is the world's first topical JAK inhibitor for treatment of atopic dermatitis (AD) that suppresses the overactivation of immune responses. In January 2023, clinical trial results for patients with atopic dermatitis aged 6 months to 2 years were added to the drug package insert.

ANTEBATE Topical corticosteroid



ANTEBETE is a treatment that improves the symptoms in patients with skin disease, such as atopic dermatitis and contact dermatitis, by suppressing inflammation.



Torii in Numbers



TORII PHARMACEUTICAL CO., LTD. INTEGRATED REPORT 2023

23.7

9.8

FY2023

5